Teclistamab
A Study of Outpatient Administration of Teclistamab, a BCMA-targeting Bispecific Antibody, in Multiple Myeloma Patients
What's the purpose of the trial?
This is a phase II study to evaluate the Outpatient Administration of Teclistamab in Multiple Myeloma Patients
Trial status
Accepting patients
Phase
Phase 2
Enrollment
75
Last Updated
2 weeks ago
Participating Centers
There are 12 centers participating in this trial. Enter a location below to find the closest center.
Experimental Treatments
Learn more about the experimental treatments being evaluated in this clinical trial.
- Teclistamab is a bispecific antibody that targets BCMA, which is expressed in mature B lymphocytes, and CD3, which is expressed on T-cells.
- Tocilizumab is an immunosuppressive drug that is used to treat several different indications.
Arms / Cohorts
Explore eligibility, treatments and learn more about potential cohorts.
Accepting patients
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.